BrightGene Ebit from 2010 to 2025

688166 Stock   30.92  1.21  4.07%   
BrightGene Bio's EBIT is increasing over the years with slightly volatile fluctuation. EBIT is expected to dwindle to about 147.1 M. From 2010 to 2025 BrightGene Bio EBIT quarterly data regression line had arithmetic mean of  111,943,453 and r-squared of  0.73. View All Fundamentals
 
EBIT  
First Reported
2010-12-31
Previous Quarter
266.1 M
Current Value
147.1 M
Quarterly Volatility
90.8 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check BrightGene Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BrightGene Bio's main balance sheet or income statement drivers, such as Tax Provision of 14.9 M, Interest Income of 21.7 M or Interest Expense of 53.6 M, as well as many indicators such as . BrightGene financial statements analysis is a perfect complement when working with BrightGene Bio Valuation or Volatility modules.
  
This module can also supplement various BrightGene Bio Technical models . Check out the analysis of BrightGene Bio Correlation against competitors.

Currently Active Assets on Macroaxis

Other Information on Investing in BrightGene Stock

BrightGene Bio financial ratios help investors to determine whether BrightGene Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BrightGene with respect to the benefits of owning BrightGene Bio security.